Modern Diagnostic & Research Centre Board Approves Extension of IPO Proceeds Utilization and Working Capital Allocation

Modern Diagnostic & Research Centre Limited convened a Board of Directors meeting on May 13, 2026, during which several significant resolutions were considered and approved. The meeting commenced at 11:03 A.M. and concluded at 11:17 A.M., covering matters related to IPO proceeds utilization, working capital funding, and a discussion on system disruptions.

Key Resolutions Approved

The board addressed three principal agenda items during the meeting. The following table summarizes the matters considered and approved:

Agenda Item: Details IPO Proceeds Utilization: Approved extension of time for utilization of net issue proceeds and completion of project as stated in the prospectus Working Capital Funding: Approved utilization of funds under General Corporate Purpose (GCP) for working capital requirements System Faults Discussion: Discussion regarding faults in the company's hardware and software systems causing temporary shutdown, subsequently restored/recovered

Extension of Net Issue Proceeds Utilization

The board approved a resolution granting an extension of time for the utilization of net issue proceeds and the completion of the project as outlined in the company's prospectus. This resolution reflects the board's intent to align project timelines with the originally stated objectives under the applicable regulatory framework.

Working Capital Allocation Under GCP

In a related resolution, the board approved the utilization of funds earmarked under the General Corporate Purpose (GCP) head for working capital requirements. This decision enables the company to deploy a portion of its raised funds toward meeting its operational funding needs.

Hardware and Software System Disruptions

As part of the any other business agenda, the board discussed faults in the company's hardware and software systems. These faults resulted in an unexpected shutdown of certain systems for a temporary period. The board noted that the affected systems were subsequently restored and recovered. The matter was discussed in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring timely disclosure to stakeholders.

Regulatory Compliance

The board meeting outcome was communicated to BSE Limited in compliance with Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was signed by Devendra Singh Yadav, Managing Director (DIN: 01254395), on May 13, 2026.

Modern Diagnostic & Research Centre Limited has issued a clarification to BSE Limited regarding significant price movement in its securities, stating that the fluctuations are purely market-driven with no undisclosed information affecting the stock performance.

BSE Inquiry and Company Response

The clarification came in response to BSE's letter bearing reference number L/SURV/ONL/PV/APJ/2026-2027/3542 dated April 8, 2026, which sought explanation for the significant movement in the company's share price across exchanges. The response was submitted on April 9, 2026, by Chairman cum Managing Director Devendra Singh Yadav from the company's Gurgaon office.

Compliance and Disclosure Status

The company emphasized its adherence to regulatory requirements and transparency standards:

Parameter Status SEBI (LODR) Regulations Compliance Fully compliant Material Event Reporting Promptly disclosed Price-Sensitive Information None undisclosed Pending Announcements None requiring disclosure

Management's Position on Price Movement

The management clarified that the increase in the company's scrip price is entirely due to market conditions and is absolutely market-driven. The company stated that there is no undisclosed price-sensitive information or any impending announcement or corporate action that could influence the stock's price behavior.

Regulatory Assurance

Modern Diagnostic and Research Centre Limited reaffirmed its commitment to maintaining transparency with stock exchanges. The company assured that it will continue to promptly inform exchanges of all material events, information, and actions as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The formal communication was signed by Devendra Singh Yadav, Chairman cum Managing Director (DIN: 01254395), reinforcing the company's position that the management is not connected with any price increase or decrease in the company's securities.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.